Brief: FDA Authorizes Phase II Study For Natrunix In Rheumatoid Arthritis Patients
22/05/2023 14:13
May 22 (Reuters) - XBiotech Inc XBIT.O :
* FDA AUTHORIZES PHASE II STUDY FOR NATRUNIX IN RHEUMATOID
ARTHRITIS PATIENTS
Source text for Eikon: ID:nGNE4cM1H3
Further company coverage: XBIT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke